This book provides an update on heterocyclic compounds that serve as key components of anti-cancer agents administered in pre-clinical settings. Many of the compounds highlighted in the book are being actively investigated for the bioactive properties against a range of cancer cell lines. There is potential for heterocyclic compounds to design agents that can target specific molecules to treat different types of cancers. Chapters are contributed by experts in pharmaceutical chemistry and are written to give a general overview of the topic to readers involved in all levels of research and decision-making in pharmaceutical chemistry and anti-cancer drug design.

Part 2 of the book set covers these topics:

- Anticancer targets for heterocyclic lead compounds

- Coumarin hybrids for cancer treatments

- Progress in nitrogen and sulphur-based heterocyclic compounds for their anticancer activity

- Imidazole as an anticancer heterocyclic ring

- Morpholine for profiling anticancer lead compounds

- Natural products as anticancer agents

Les informations fournies dans la section � A propos du livre � peuvent faire r�f�rence � une autre �dition de ce titre.

Description de la librairie

Visitez la page d�accueil du vendeur

Informations commerciales relatives au vendeur

WRAP Ltd
Unit 4, 119 Loverock Rd, Reading, RG30 1DZ, United Kingdom

Conditions de vente et de livraison

Conditions g�n�rales de vente

TBA

Conditions d'exp�dition

Shipping costs are based on books weighing 2.2 LB, or 1 KG. If your book order is heavy or oversized, we may contact you to let you know extra shipping is required.